Literature DB >> 25031177

Expression profile analysis of hippocampal CA1 pyramidal neurons in aged Ts65Dn mice, a model of Down syndrome (DS) and Alzheimer's disease (AD).

Melissa J Alldred1, Sang Han Lee, Eva Petkova, Stephen D Ginsberg.   

Abstract

Down syndrome (DS) is caused by the triplication of human chromosome 21 (HSA21) and is the most common genetic cause of intellectual disability, with individuals having deficits in cognitive function including hippocampal learning and memory and neurodegeneration of cholinergic basal forebrain neurons, a pathological hallmark of Alzheimer's disease (AD). To date, the molecular underpinnings driving this pathology have not been elucidated. The Ts65Dn mouse is a segmental trisomy model of DS and like DS/AD pathology, displays age-related cognitive dysfunction and basal forebrain cholinergic neuron (BFCN) degeneration. To determine molecular and cellular changes important for elucidating mechanisms of neurodegeneration in DS/AD pathology, expression profiling studies were performed. Molecular fingerprinting of homogeneous populations of Cornu Ammonis 1 (CA1) pyramidal neurons was performed via laser capture microdissection followed by Terminal Continuation RNA amplification combined with custom-designed microarray analysis and subsequent validation of individual transcripts by qPCR and protein analysis via immunoblotting. Significant alterations were observed within CA1 pyramidal neurons of aged Ts65Dn mice compared to normal disomic (2N) littermates, notably in excitatory and inhibitory neurotransmission receptor families and neurotrophins, including brain-derived neurotrophic factor as well as several cognate neurotrophin receptors. Examining gene and protein expression levels after the onset of BFCN degeneration elucidated transcriptional and translational changes in neurons within a vulnerable circuit that may cause the AD-like pathology seen in DS as these individuals age, and provide rational targets for therapeutic interventions.

Entities:  

Mesh:

Year:  2014        PMID: 25031177      PMCID: PMC4297601          DOI: 10.1007/s00429-014-0839-0

Source DB:  PubMed          Journal:  Brain Struct Funct        ISSN: 1863-2653            Impact factor:   3.270


  93 in total

Review 1.  Retrograde transport redux.

Authors:  Moses V Chao
Journal:  Neuron       Date:  2003-07-03       Impact factor: 17.173

2.  Transcriptional profiling of small samples in the central nervous system.

Authors:  Stephen D Ginsberg
Journal:  Methods Mol Biol       Date:  2008

3.  Memantine normalizes several phenotypic features in the Ts65Dn mouse model of Down syndrome.

Authors:  Noemí Rueda; María Llorens-Martín; Jesús Flórez; Elsa Valdizán; Pradeep Banerjee; Jose Luis Trejo; Carmen Martínez-Cué
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

4.  Characterizations and validations of novel antibodies toward translational research.

Authors:  Reginald Williams; Joon-Yong Chung; Kris Ylaya; Gordon Whiteley; Stephen M Hewitt
Journal:  Proteomics Clin Appl       Date:  2010-03-26       Impact factor: 3.494

5.  Developmental abnormalities and age-related neurodegeneration in a mouse model of Down syndrome.

Authors:  D M Holtzman; D Santucci; J Kilbridge; J Chua-Couzens; D J Fontana; S E Daniels; R M Johnson; K Chen; Y Sun; E Carlson; E Alleva; C J Epstein; W C Mobley
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-12       Impact factor: 11.205

6.  App gene dosage modulates endosomal abnormalities of Alzheimer's disease in a segmental trisomy 16 mouse model of down syndrome.

Authors:  Anne M Cataldo; Suzana Petanceska; Corrinne M Peterhoff; Nicole B Terio; Charles J Epstein; Angela Villar; Elaine J Carlson; Matthias Staufenbiel; Ralph A Nixon
Journal:  J Neurosci       Date:  2003-07-30       Impact factor: 6.167

Review 7.  Preventing Ca2+-mediated nitrosative stress in neurodegenerative diseases: possible pharmacological strategies.

Authors:  Tomohiro Nakamura; Stuart A Lipton
Journal:  Cell Calcium       Date:  2010-01-08       Impact factor: 6.817

8.  The topography of plaques and tangles in Down's syndrome patients of different ages.

Authors:  D M Mann; P O Yates; B Marcyniuk; C R Ravindra
Journal:  Neuropathol Appl Neurobiol       Date:  1986 Sep-Oct       Impact factor: 8.090

Review 9.  Mouse models of Down syndrome as a tool to unravel the causes of mental disabilities.

Authors:  Noemí Rueda; Jesús Flórez; Carmen Martínez-Cué
Journal:  Neural Plast       Date:  2012-05-22       Impact factor: 3.599

Review 10.  Functional genomic methodologies.

Authors:  Stephen D Ginsberg; Károly Mirnics
Journal:  Prog Brain Res       Date:  2006       Impact factor: 2.453

View more
  22 in total

1.  Brain-derived neurotrophic factor (BDNF) and TrkB hippocampal gene expression are putative predictors of neuritic plaque and neurofibrillary tangle pathology.

Authors:  Stephen D Ginsberg; Michael H Malek-Ahmadi; Melissa J Alldred; Yinghua Chen; Kewei Chen; Moses V Chao; Scott E Counts; Elliott J Mufson
Journal:  Neurobiol Dis       Date:  2019-07-23       Impact factor: 5.996

2.  Maternal Choline Supplementation Alters Basal Forebrain Cholinergic Neuron Gene Expression in the Ts65Dn Mouse Model of Down Syndrome.

Authors:  Christy M Kelley; Stephen D Ginsberg; Melissa J Alldred; Barbara J Strupp; Elliott J Mufson
Journal:  Dev Neurobiol       Date:  2019-06-09       Impact factor: 3.964

3.  Long-term effects of maternal choline supplementation on CA1 pyramidal neuron gene expression in the Ts65Dn mouse model of Down syndrome and Alzheimer's disease.

Authors:  Melissa J Alldred; Helen M Chao; Sang Han Lee; Judah Beilin; Brian E Powers; Eva Petkova; Barbara J Strupp; Stephen D Ginsberg
Journal:  FASEB J       Date:  2019-06-10       Impact factor: 5.191

4.  Maternal choline supplementation in a mouse model of Down syndrome: Effects on attention and nucleus basalis/substantia innominata neuron morphology in adult offspring.

Authors:  Brian E Powers; Christy M Kelley; Ramon Velazquez; Jessica A Ash; Myla S Strawderman; Melissa J Alldred; Stephen D Ginsberg; Elliott J Mufson; Barbara J Strupp
Journal:  Neuroscience       Date:  2016-11-10       Impact factor: 3.590

Review 5.  Can Animal Models Inform on the Relationship between Depression and Alzheimer Disease?

Authors:  Jennifer N K Nyarko; Maa O Quartey; Glen B Baker; Darrell D Mousseau
Journal:  Can J Psychiatry       Date:  2018-04-23       Impact factor: 4.356

6.  Expression profile analysis of vulnerable CA1 pyramidal neurons in young-Middle-Aged Ts65Dn mice.

Authors:  Melissa J Alldred; Sang Han Lee; Eva Petkova; Stephen D Ginsberg
Journal:  J Comp Neurol       Date:  2014-08-30       Impact factor: 3.215

7.  Reduction of β-amyloid and γ-secretase by calorie restriction in female Tg2576 mice.

Authors:  Marissa J Schafer; Melissa J Alldred; Sang Han Lee; Michael E Calhoun; Eva Petkova; Paul M Mathews; Stephen D Ginsberg
Journal:  Neurobiol Aging       Date:  2014-12-04       Impact factor: 4.673

8.  CA1 pyramidal neuron gene expression mosaics in the Ts65Dn murine model of Down syndrome and Alzheimer's disease following maternal choline supplementation.

Authors:  Melissa J Alldred; Helen M Chao; Sang Han Lee; Judah Beilin; Brian E Powers; Eva Petkova; Barbara J Strupp; Stephen D Ginsberg
Journal:  Hippocampus       Date:  2018-02-12       Impact factor: 3.899

Review 9.  Molecular and cellular pathophysiology of preclinical Alzheimer's disease.

Authors:  Elliott J Mufson; Milos D Ikonomovic; Scott E Counts; Sylvia E Perez; Michael Malek-Ahmadi; Stephen W Scheff; Stephen D Ginsberg
Journal:  Behav Brain Res       Date:  2016-05-13       Impact factor: 3.332

10.  Selective decline of neurotrophin and neurotrophin receptor genes within CA1 pyramidal neurons and hippocampus proper: Correlation with cognitive performance and neuropathology in mild cognitive impairment and Alzheimer's disease.

Authors:  Stephen D Ginsberg; Michael H Malek-Ahmadi; Melissa J Alldred; Shaoli Che; Irina Elarova; Yinghua Chen; Freddy Jeanneteau; Thorsten M Kranz; Moses V Chao; Scott E Counts; Elliott J Mufson
Journal:  Hippocampus       Date:  2017-09-27       Impact factor: 3.899

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.